Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets

Cancer Letters

Volumn 257, Issue 2, 2007, Pages 157-164

  Lu, Yi ^a   Yao, Hang Ping ^a   Wang, Ming Hai ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Alternative splicing; Invasive growth; Oncogenic signal; Receptor tyrosine kinase; Therapeutical target

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOGEN SYNTHASE KINASE 3BETA; PF 2341066; PFA 2341066; PHA 665752; PROTEIN TYROSINE KINASE; RON RECEPTOR TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CARCINOMA; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; COLON CANCER; DRUG POTENCY; DRUG TARGETING; ENZYME SPECIFICITY; GENE DELETION; GENE EXPRESSION; GENE SILENCING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; NONHUMAN; ONCOGENE; PATHOGENESIS; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; RNA SPLICING; SHORT SURVEY; TISSUE MICROARRAY;

EID: 35148819860     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.08.007     Document Type: Review

References (52)

1. Ronsin C., Muscatelli F., Mattei M.G., et al. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8 (1993) 1195-1202
2. Iwama A., Okano K., Sudo T., et al. Molecular cloning of a novel receptor tyrosine kinase gene, STK, derived from enriched hematopoietic stem cells. Blood 83 (1994) 3160-3169
3. Skeel A., Yoshimura T., Showalter S.D., Tanaka S., Appella E., and Leonard E.J. Macrophage-stimulating protein: purification, partial amino acid sequence, and cellular activity. J. Exp. Med. 173 (1991) 1227-1234
4. Yoshimua T., Yuhki N., Wang M.H., et al. Cloning sequencing and expression of human macrophage stimulating protein [MSP] confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J. Biol. Chem. 268 (1993) 15462-15468
5. Gaudino G., Follenzi A., Naldini L., et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 13 (1994) 3524-3532
6. Wang M.H., Ronsin C., Gesnel M.C., et al. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science 266 (1994) 117-119
7. Degen F.S.J., Stuart L.A., Han S., and Jamison C.S. Characterization of the mouse cDNA and gene coding for a hepatocyte growth factor-like protein: expression during development. Biochemistry 30 (1991) 9781-9791
8. Angeloni D., Danilkovitch-Miagkova A., Ivanov S.V., et al. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer 29 (2000) 147-156
9. Wei M.H., Latif F., Bader S., Kashuba V., et al. Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res. 56 (1996) 1487-1492
10. Muraoka R.S., Sun W.Y., and Colbert M.C. The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. J. Clin. Invest. 103 (1999) 1277-1285
11. Wang M.H., Zhou Y.Q., and Chen Y.Q. Macrophage-stimulating protein and RON receptor tyrosine kinase potential regulators of macrophage inflammatory activities. Scand. J. Immunol. 56 (2002) 545-553
12. Wang M.H., Wang D., and Chen Y.Q. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 24 (2003) 1291-1300
13. O'Toole J.M., Rabenau K.E., Burns K., et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 66 (2006) 9162-9170
14. Camp E.R., Yang A., Gray M.J., et al. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer 109 (2007) 1030-1039
15. Pajares M.J., Ezponda T., Catena R., Calvo A., Pio R., and Montuenga L.M. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol. 8 (2007) 349-357
16. Zhou Y.Q., He C., Chen Y.Q., et al. Altered expression of the RON receptor tyrosine kniase in primary human colorectal adenocarcinomas: generation of different splicing variants and their oncogenic potential. Oncogene 22 (2003) 186-197
17. Wang M.H., Lao W.F., Wang D., et al. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain. Can. Biol. Ther. 6 (2007)
18. Angeloni D., Duh F.M., Moody M., et al. C to A single nucleotide polymorphism in intron 18 of the human MST1R (RON) gene that maps at 3p21.3. Mol. Cell. Probes 17 (2003) 55-57
19. Collesi C., Santoro M.M., Gaudino G., et al. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol. Cell. Biol. 16 (1996) 5518-5526
20. Wang M.H., Kurtz A.L., and Chen Y.Q. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 21 (2000) 1507-1512
21. Xu X.M., Zhou Y.Q., and Wang M.H. Mechanisms of cytoplasmic β-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from nantes tyrosine kinase. J. Biol. Chem. 280 (2005) 25087-25094
22. Xu X.M., Wang D., Shen Q., Chen Y.Q., and Wang M.H. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 23 (2004) 8464-8474
23. Bienz M., and Clevers H. Linking colorectal cancer to Wnt signaling. Cell 103 (2000) 311-320
24. Bardella C., Costa B., Maggiora P., et al. RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res. 64 (2004) 5154-5161
25. Persons D.A., Paulson R.F., Loyd M.R., et al. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat. Genet. 23 (1999) 159-165
26. Angeloni D., Danilkovitch-Miagkova A., Ivanova T., et al. Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene 26 (2007) 4499-4512
27. Ghigna C., Giordano S., Shen H.H., et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol. Cell 20 (2005) 881-890
28. Karni R., de Stanchina E., Lowe S.W., et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14 (2007) 185-193
29. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23 (2001) 912-923
30. Wang D., Shen Q., Chen Y.Q., et al. Collaborative activities of macrophage-stimulating protein and transforming growth factor-b1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene 23 (2004) 1668-1680
31. Li B.Q., Wang M.H., Kung F.X., et al. Macrophage-stimulating protein activates Ras by both activation and translocation of SOS nucleotide exchange factor. Biochem. Biophys. Res. Commun. 216 (1996) 110-118
32. Yao H.P., Luo Y.L., Feng L., et al. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Can. Biol. Ther. 5 (2006) 1179-1186
33. Wang M.H., Montero-Julian F.A., Dauny I., and Leonard E.J. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene 13 (1996) 2167-2175
34. Santoro M.M., Penengo L., Minetto M., Orecchia S., Cilli M., and Gaudino G. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 17 (1998) 741-749
35. Santoro M.M., Gaudino G., and Marchisio P.C. The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev. Cell 5 (2003) 257-271
36. Penengo L., Rubin C., Yarden Y., and Gaudino G. c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene 22 (2003) 3669-3679
37. Thien C.B., and Langdon W.Y. c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem. J. 391 (2005) 153-166
38. Germano S., Barberis D., Santoro M.M., et al. Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling. J. Biol. Chem. 281 (2006) 21710-21719
39. Wang W., Marimuthu A., Tsai J., et al. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl. Aacd. Sci. USA 103 (2006) 3563-3568
40. Ponzetto C., Bardelli A., Zhen Z., et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77 (1994) 261-271
41. Santoro M.M., Penengo L., Orecchia S., Cilli M., and Gaudino G. The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site. Oncogene 19 (2000) 5208-5211
42. Noriko Y., Irene I., Michael J.H., et al. The C terminus of RON tyrosine kinase plays an auto-inhibitory role. J. Biol. Chem. 280 (2005) 8893-8900
43. Sawyers C. Targeted cancer therapy. Nature 432 (2004) 294-297
44. Maggiora P., Marchio S., Stella M.C., et al. Overexpression of the RON gene in human breast carcinoma. Oncogene 16 (1998) 2927-2933
45. M.H. Wang, L. Wei, Y.L. Luo, H.P. Yao, Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumorigenic phenotypes in thyroid cancer cells, accepted for publication.
46. Camp E.R., Liu W., Fan F., Yang A., Somcio R., and Ellis L.M. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann. Surg. Oncol. 12 (2005) 273-281
47. Chen Y.Q., Zhou Y.Q., Fu L.H., Wang D., and Wang M.H. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Carcinogenesis 23 (2002) 1811-1819
48. Zinser G.M., Leonis M.A., Toney K., et al. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 66 (2006) 11967-11974
49. Matzke A., Herrlich P., Ponta H., and Orian-Rousseau V. A five-amino-acid peptide blocks Met- and Ron-dependent cell migration. Cancer Res. 65 (2005) 6105-6110
50. Angeloni D., Danilkovitch-Miagkova A., et al. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J. Biol. Chem. 279 (2004) 3726-3732
51. Christensen J.G., Schreck R., Burrows J., Kuruganti P., Chan E., et al. A selective small molecule inhibitors of c-met kinase inhibits c-met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63 (2003) 7345-7355
52. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., et al. PF-2341066 exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67 (2007) 4408-4417